1-3 of 3
Simon Chivers
Close
Sort by
Journal Articles

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

Francesca Zammarchi, Simon Corbett, Lauren Adams, Peter C. Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. Britten, Carin E. G. Havenith, Simon Chivers, Francois D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley, Patrick H. van Berkel
Journal: Blood
Blood (2018) 131 (10): 1094–1105.
https://doi.org/10.1182/blood-2017-10-813493
Published: 2018
Includes: Supplemental data
Journal Articles

hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.

Francesca Zammarchi, PhD, Simon Corbett, Lauren Adams, Maria Mellinas-Gomez, PhD, Peter Tyrer, PhD, Sandamali Dissanayake, Simone Sims, Karin Havenith, PhD, Simon Chivers, PhD, David G Willimas, PhD, Philip W Howard, PhD, John A. Hartley, PhD, Patrick van Berkel, PhD
Journal: Blood
Blood (2016) 128 (22): 4176.
https://doi.org/10.1182/blood.V128.22.4176.4176
Published: 2016
Journal Articles

Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies

Francesca Zammarchi, PhD, David G. Williams, PhD, Lauren Adams, Karin Havenith, PhD, Simon Chivers, PhD, Francois D'Hooge, PhD, Philip W. Howard, PhD, John A. Hartley, PhD, Patrick H. van Berkel, PhD
Journal: Blood
Blood (2015) 126 (23): 1564.
https://doi.org/10.1182/blood.V126.23.1564.1564
Published: 2015